FCCC LOGO Faculty Publications
Rimm DL , Han G , Taube JM , Yi ES , Bridge JA , Flieder DB , Homer R , Roden AC , Hirsch FR , Wistuba II , Pusztai L
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
Breast Cancer Res. 2019 Jun 13;21(1) :72
PMID: 31196152    PMCID: PMC6567382   
Back to previous list
Abstract
The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.
Notes
1465-542x Rimm, David L ORCID: http://orcid.org/0000-0001-5820-4397 Han, Gang Taube, Janis M Yi, Eunhee S Bridge, Julia A Flieder, Douglas B Homer, Robert Roden, Anja C Hirsch, Fred R Wistuba, Ignacio I Pusztai, Lajos P30 CA016359/CA/NCI NIH HHS/United States P50 CA196530/CA/NCI NIH HHS/United States P30CA016359/National Cancer Institute P50CA196530/National Cancer Institute Journal Article England Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.